The FDA's Allergenic Products Advisory Committee, or APAC, is slated to determine whether or not to recommend approval of Palforzia, an experimental peanut allergy drug, developed by Aimmune Therapeutics Inc. (AIMT), on September 13, 2019.
from RTT - Biotech https://ift.tt/2Q4VPX6
via IFTTT
No comments:
Post a Comment